Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

TORONTO, Dec. 4, 2024 /CNW/ - Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.

About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

Eli Lilly said on Wednesday that a clinical trial had shown that patients taking its weight-loss drug Zepbound (tirzepatide) ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...